➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Harvard Business School
Colorcon
Boehringer Ingelheim
Express Scripts

Last Updated: November 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Maxacalcitol

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Maxacalcitol?

Maxacalcitol is an investigational drug.

There have been 4 clinical trials for Maxacalcitol. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2011.

The most common disease conditions in clinical trials are Neoplasm Metastasis, Hyperparathyroidism, Secondary, and Hyperparathyroidism. The leading clinical trial sponsors are Abbott, AbbVie (prior sponsor, Abbott), and Kumamoto University.

There are one hundred and seventy-one US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Maxacalcitol
TitleSponsorPhase
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary HyperparathyroidismAbbVie (prior sponsor, Abbott)Phase 3
Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary HyperparathyroidismAbbottPhase 2
Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving HemodialysisAbbott Japan Co.,LtdPhase 2

See all Maxacalcitol clinical trials

Clinical Trial Summary for Maxacalcitol

Top disease conditions for Maxacalcitol
Top clinical trial sponsors for Maxacalcitol

See all Maxacalcitol clinical trials

US Patents for Maxacalcitol

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Maxacalcitol   Start Trial Sprayable topical carrier and composition comprising phosphatidylcholine LIPIDOR AB (Stockholm, SE)   Start Trial
Maxacalcitol   Start Trial Combination of low dose 2-methylene-19-nor-(20S)1.alpha., 25-dihydroxyvitamin D.sub.3 and calcimimetics to treat secondary hyperparathyroidism Wisconsin Alumni Research Foundation (Madison, WI)   Start Trial
Maxacalcitol   Start Trial Composition comprising a combination of DNA methylation inhibitor and a vitamin D receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse Institut National de la Sante et de la Recherche Medicale (INSERM) (Paris, FR) Centre National de la Recherche Scientifique (C.N.R.S.) (Paris, FR) Universite Paris Descartes (Paris, FR) Foundation Imagine (Paris, FR) Universite Paris Diderot--Paris 7 (Paris, FR) Universite Paris--Sud (Orsay, FR) Assistance Publique-Hopitaux de Paris (APHP) (Paris, FR)   Start Trial
Maxacalcitol   Start Trial Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid Leo Pharma A/S (Ballerup, DK)   Start Trial
Maxacalcitol   Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Start Trial
Maxacalcitol   Start Trial Vitamin D receptor/SMAD genomic circuit gates fibrotic response Salk Institute for Biological Studies (La Jolla, CA) The University of Sydney (Sydney, AU)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Maxacalcitol

Drugname Country Document Number Estimated Expiration Related US Patent
Maxacalcitol Australia 2012251135 2031-05-02   Start Trial
Maxacalcitol Australia 2014349256 2031-05-02   Start Trial
Maxacalcitol Australia 2014349257 2031-05-02   Start Trial
Maxacalcitol Canada 2834301 2031-05-02   Start Trial
Maxacalcitol Canada 2929865 2031-05-02   Start Trial
Maxacalcitol Canada 2929867 2031-05-02   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Harvard Business School
Colorcon
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.